[{"id":"2aaa57e7-ec75-44f1-85ec-6f02f055294b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06590558","created_at":"2025-02-25T16:41:20.201Z","updated_at":"2025-02-25T16:41:20.201Z","phase":"Phase 1","brief_title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT06590558","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RIPK1","pipe":"","alterations":" ","tags":["RIPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • tolinapant (ASTX660)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/04/2025","start_date":" 08/04/2025","primary_txt":" Primary completion: 05/17/2027","primary_completion_date":" 05/17/2027","study_txt":" Completion: 05/17/2027","study_completion_date":" 05/17/2027","last_update_posted":"2025-02-06"}]